Figure EV2. Smad4 LNA administration retards the progression of mouse type 2 diabetic nephropathy.

• A–C
  Changes in body weight, fasting blood glucose levels and plasma insulin in age‐matched, control‐LNA (CTL LNA)‐treated or Smad4 LNA‐treated type 2 diabetic eNOS^−/− mice.
• D, E
  Glucose tolerance test (E) and quantification of glucose tolerance test (D) in age‐matched, control‐LNA (CTL LNA)‐treated or Smad4 LNA‐treated type 2 diabetic eNOS^−/− mice.

Data information: One‐way ANOVA was performed. Data are shown as mean ± SD from groups of 6 mice.